Novocure Ltd (NVCR)

NovoCure Limited (NVCR) dropped by 7.53% from $14.08 to $13.02 in the trading on Thursday October 26, 2023. The reason why NVCR stock down today is due to its disappointing third-quarter results.

• Total revenue of slightly over $127 million. That represented a year-over-year decline of 3%, and missed the consensus analyst estimate of almost $129 million.
• Net loss amounted to $49.5 million, or $0.46 per share. While this bettered the average prognosticator forecast of a $0.53-per-share loss, it was nearly double the $26.6 million shortfall in the same quarter of 2022.
• Sales and marketing expenses saw a sharp (40%) year-over-year increase. Research and development/clinical trial spending, meanwhile, inched up by 3%.

NovoCure's stock plummeted 37.50% after disappointing phase 3 results for its TTFields therapy in platinum-resistant ovarian cancer, failing to meet the survival target. Despite success in non-small cell lung cancer, the company aims to gain FDA approval, while also noting potential benefits in specific patient groups for earlier treatment.

https://www.fool.com/investing/2023/08/28/why-novocure-stock-is-crashing-today/

NovoCure Limited (NVCR) tumbled nearly 16% to $33.93 today after the company posted a notably deeper net loss in its freshly reported quarter, while its revenue fell.

https://www.fool.com/investing/2023/07/27/why-novocure-stock-tumbled-by-nearly-16-today/

NVCR's stock fell 43.04% after the company published its latest clinical data on Tumor Treating Fields therapy. Despite the positive results, the investors were skeptical about its therapy's advantage over the conventional one due to the unideal structure of the trial.

https://www.fool.com/investing/2023/06/06/these-2-nasdaq-stocks-are-plunging-heres-why/